PharmaEngine Inc
PharmaEngine Inc. is a Taiwan-listed virtual biopharmaceutical company that develops and commercializes precision oncology therapies, anchored by the global ONIVYDE franchise (liposomal irinotecan, approved in 50+ countries for metastatic pancreatic cancer) and an emerging pipeline of PRMT5 and CHK1 inhibitors.
- Company typePublic
- Founded2003
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PharmaEngine Inc does
PharmaEngine Inc. is a Taiwan-incorporated, publicly listed (Taiwan Stock Exchange: TWO:4162) biopharmaceutical company founded in February 2003 that operates under a "Virtual Pharmaceutical Company" business model. The company focuses on oncology drug development and commercialization, leveraging international strategic alliances to minimize capital expenditure on manufacturing and large-scale commercial infrastructure. Headquartered in Taipei with 33 employees as of the 2024 Annual Report, PharmaEngine is led by President & CEO Hong-Ren Wang, Ph.D., and Chairperson Jan-Yau Hsu. The company markets ONIVYDE® (liposomal irinotecan), a topoisomerase I inhibitor approved in over 50 countries for metastatic pancreatic cancer in both second-line (post-gemcitabine) and first-line (NALIRIFOX regimen) settings.
Revenue is generated primarily through royalties and milestone payments from licensing partners Ipsen (US/Canada commercialization) and Servier (global ex-US/Canada/Taiwan commercialization), supplemented by direct product sales in Taiwan through PharmaEngine's own sales organization and an exclusive Taiwan distribution arrangement for LIPORAXEL® (oral paclitaxel) with Haihe Biopharma. In February 2025 the company received a US$50 million milestone payment from Ipsen after ONIVYDE's 2024 sales in Europe and Asia triggered the second sales milestone. The R&D pipeline comprises PEP07, a brain-penetrant CHK1 inhibitor licensed from Sentinel Oncology (UK) currently in Phase I for hematologic cancers (AML, MCL) and solid tumors, and PEP08, a second-generation MTA-cooperative PRMT5 inhibitor discovered via XtalPi Holdings' AI- and robotics-powered platform that began Phase I dosing in October 2025 as PharmaEngine's first internally developed clinical asset. A second synthetic lethality program has been initiated under the expanded XtalPi partnership.
The company holds 19 in-licensed invention patents plus 1 independently granted patent and 9 pending applications, along with 14 registered trademarks. PharmaEngine is ISO 27001:2022 certified (renewed January 2026), complies with GMP/GDP/GLP/GCP quality frameworks, and operates under a board structure with representatives from the Taiwan National Development Fund, TTY Biopharm, and independent directors with government and academic backgrounds. In 2025 the company was recognized among Taiwan's Best-In-Class companies by the Taiwan Institute of Directors, ranking first in Top 10 Profit Champions and second in Top 10 Growth Companies.
PharmaEngine Inc firmographics
Firmographics- Name
- PharmaEngine Inc
- Legal name
- PharmaEngine Inc.
- Website
- https://pharmaengine.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaEngine Inc. is a Taiwan-listed virtual biopharmaceutical company that develops and commercializes precision oncology therapies, anchored by the global ONIVYDE franchise (liposomal irinotecan, approved in 50+ countries for metastatic pancreatic cancer) and an emerging pipeline of PRMT5 and CHK1 inhibitors.
- Ownership category
- akta.pro rank
PharmaEngine Inc industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where PharmaEngine Inc is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
PharmaEngine Inc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- ONIVYDE Royalties and Milestone Payments: PharmaEngine receives royalties and milestone payments from licensing partners Ipsen (US/Canada) and Servier (global markets excluding US, Canada, Taiwan) based on ONIVYDE sales and achievement of development/regulatory milestones. In 2025, PharmaEngine received US$50 million milestone payment for ONIVYDE's 2024 sales in Europe and Asia reaching the second sales milestone.
- ONIVYDE Product Sales (Taiwan): PharmaEngine handles direct commercialization of ONIVYDE in Taiwan, generating product revenue through its own sales and marketing efforts.
- LIPORAXEL Distribution (Taiwan): PharmaEngine holds exclusive distribution rights for LIPORAXEL (paclitaxel oral solution) in Taiwan, handling local NDA filing, sales, and marketing, creating an additional product revenue stream.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
PharmaEngine Inc product offering
Product offeringCore offering
PharmaEngine develops and commercializes precision oncology therapies using a Virtual Pharmaceutical Company model. Its commercial product ONIVYDE® is a liposomal irinotecan formulation approved in 50+ countries for metastatic pancreatic adenocarcinoma. The pipeline includes PEP07 (CHK1 inhibitor, licensed from Sentinel Oncology) and PEP08 (first in-house developed PRMT5:MTA inhibitor, co-developed with XtalPi's AI platform), both in Phase I trials. PharmaEngine also distributes LIPORAXEL® (oral paclitaxel) in Taiwan.
Product overview
PharmaEngine Inc operates as a Virtual Pharmaceutical Company focused on oncology drug development and commercialization. The company's portfolio consists of one commercial product (ONIVYDE®) and multiple pipeline candidates in clinical development. ONIVYDE® is a liposomal irinotecan formulation for pancreatic cancer treatment marketed globally through partnerships with Ipsen and Servier. The R&D pipeline includes PEP08, a first-in-house developed PRMT5 inhibitor targeting MTAP-deleted cancers currently in Phase I trials, and PEP07, an oral CHK1 inhibitor licensed from Sentinel Oncology also in Phase I trials for hematological and solid tumors. Additionally, PharmaEngine distributes LIPORAXEL® (paclitaxel oral solution) in Taiwan under a partnership with Haihe Biopharma.
Differentiator
Problem solved
Functional benefit
Products and services
- ONIVYDE® (Irinotecan liposome injection) Liposomal formulation of irinotecan (a topoisomerase I inhibitor) encapsulated in nanoparticles that accumulate in tumors and release the drug slowly. Approved for treatment of metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin after disease progression following gemcitabine-based therapy (second-line) and as first-line therapy in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen). Marketed globally through partners Ipsen (US/Canada) and Servier (rest of world) and directly by PharmaEngine in Taiwan.
- PEP08 (PRMT5:MTA inhibitor)
Quantifiable outcome
- NAPOLI-3 Phase III trial: NALIRIFOX showed statistically significant improvement in overall survival (median OS 11.1 vs 9.2 months, HR=0.83, p=0.04) and progression-free survival (median PFS 7.4 vs 5.6 months, HR=0.69, p<0.0001) versus nab-paclitaxel+gemcitabine in previously untreated metastatic PDAC
- +2 more outcomes
Companies that use PharmaEngine Inc
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
PharmaEngine Inc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
PharmaEngine Inc partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- XtalPi HoldingscoreXtalPi and PharmaEngine partnership enabled discovery of PEP08, a next-generation PRMT5 inhibitor using XtalPi's AI- and robotics-powered platform. PEP08 received clinical clearance in June 2025 and began enrollment in Phase I solid tumor trial in October 2025. Partnership has expanded to initiate a second synthetic lethality project targeting a different undisclosed mechanism. XtalPi reported RMB 802.6 million revenue in 2025 (201.2% increase) driven by collaborations including the PharmaEngine partnership.
- Haihe Biopharma / Shanghai RMX Biopharma Co. Ltd.minorPharmaEngine entered an exclusive distribution agreement for LIPORAXEL (paclitaxel oral solution) in Taiwan. PharmaEngine is solely responsible for NDA filing, sales, and marketing of LIPORAXEL in Taiwan. LIPORAXEL is developed by Daehwa Pharmaceutical (South Korea) using DH-LASED drug delivery platform and distributed in Taiwan through Haihe's subsidiary Shanghai RMX Biopharma.
- ServiercoreServier is responsible for global commercialization of ONIVYDE outside of US, Canada, and Taiwan. In March 2024, Servier obtained EMA CHMP positive opinion and Taiwan TFDA approval for ONIVYDE NALIRIFOX as first-line treatment for metastatic pancreatic adenocarcinoma. PharmaEngine receives royalties and milestone payments from Servier's sales outside Taiwan.
- IpsencoreIpsen holds exclusive commercialization rights for ONIVYDE in the US and Canada for current and all potential future indications. On February 13, 2024, Ipsen received US FDA approval for ONIVYDE (NALIRIFOX) as first-line treatment for metastatic PDAC. PharmaEngine receives royalties and milestone payments from Ipsen based on net sales and achievement of development milestones.
- Sentinel Oncology LimitedcorePharmaEngine exercised option for worldwide exclusive license for PEP07 (CHK1 inhibitor) from Sentinel Oncology in September 2022. PEP07 is undergoing Phase I clinical trials for hematologic cancers (AML, MCL) and solid tumors. Sentinel Oncology eligible to receive up to US$140.5 million in upfront, development, regulatory and sales milestones plus tiered royalties on worldwide net product sales.
- NanobiotixminorPartnership for PEP503 (NBTXR3) in Asia-Pacific was terminated in March 2021. PharmaEngine granted back to Nanobiotix exclusive rights for development and commercialization of NBTXR3 in Asia-Pacific region. PharmaEngine is entitled to receive US$12.5 million in milestone payments and tiered royalties on net product sales in the region upon achievement of certain milestones.
- Daehwa Pharmaceutical Co. Ltd.minorDaehwa Pharmaceutical (South Korea) developed LIPORAXEL using its DH-LASED (Lipid Self-Emulsified Drug Delivery) technology platform. Shanghai RMX Biopharma (Haihe subsidiary) in-licensed rights for development, manufacturing, and commercialization in China, Taiwan, Hong Kong, and Thailand. PharmaEngine holds exclusive distribution rights for Taiwan.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
PharmaEngine Inc competitors and assessment
Company assessmentBroad incumbents
- Ipsen: Ipsen is PharmaEngine's exclusive commercialization partner for ONIVYDE in the US and Canada and a broader specialty oncology incumbent. Both companies operate in the same oncology pharmaceutical space and have a direct economic relationship through ONIVYDE royalties and milestones.
- Servier: Servier is PharmaEngine's global commercialization partner for ONIVYDE outside the US, Canada, and Taiwan, and is a major European pharmaceutical company with significant oncology operations. Both companies share direct economics on ONIVYDE sales outside the named territories.
- PharmaMar: PharmaMar is a European specialty oncology biopharmaceutical company developing and commercializing marine-derived oncology drugs. Both companies are specialty oncology players relying on licensing/partnerships for global reach.
Direct peers
- Nuvectis Pharma: Nuvectis Pharma is a US clinical-stage precision oncology company developing a PRMT5 inhibitor (NUV-1516) for MTAP-deleted and other cancers. It is a direct competitor to PharmaEngine's PEP08 in the same target class and indication.
- Cardiff Oncology: Cardiff Oncology is developing onvansertib, a CHK1/PLK1 inhibitor, in metastatic colorectal and other cancers. It is a direct competitor to PharmaEngine's PEP07 in the CHK1 inhibitor space and a similarly-sized clinical-stage oncology company.
- IDEAYA Biosciences: IDEAYA Biosciences is a clinical-stage synthetic lethality and precision oncology company developing MAT2A and PRMT5 inhibitors (e.g., IDE397) for MTAP-deleted tumors. It is a direct competitor to PharmaEngine's PEP08 in the synthetic lethality oncology space.
- Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage company developing a synthetic lethality platform targeting chromatin regulatory biology in oncology, including programs potentially relevant to PRMT5/MTAP biology. It is comparable to PharmaEngine's synthetic lethality R&D focus.
- Repare Therapeutics: Repare Therapeutics is a clinical-stage precision oncology company building a synthetic lethality platform targeting DDR and related mechanisms (e.g., PKMYT1, ATR). Its synthetic lethality and DDR focus is directly comparable to PharmaEngine's PEP07 (CHK1/DDR) and PEP08 (synthetic lethality) programs.
Regional players
- TTY Biopharm: TTY Biopharm is a Taiwan-based specialty pharmaceutical company with oncology and specialty drug operations and is a meaningful shareholder in PharmaEngine. It is a regional Taiwan peer with overlapping cancer drug distribution and development interests.
Others
- XtalPi Holdings: XtalPi is PharmaEngine's strategic partner for AI- and robotics-powered small-molecule discovery that produced PEP08. It is an enabling/technology peer — comparable not as a competitor but as a closely tied discovery collaborator in the AI-enabled drug discovery ecosystem.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PharmaEngine Inc social profiles
Digital presencePharmaEngine Inc compliance and trust
Trust signalCompliance2 records
PharmaEngine Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaEngine Inc leadership team
Management profileNumber of profiles
Profiles18 records
PharmaEngine Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaEngine Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaEngine Inc
What does PharmaEngine Inc do?
PharmaEngine develops and commercializes precision oncology therapies using a Virtual Pharmaceutical Company model. Its commercial product ONIVYDE® is a liposomal irinotecan formulation approved in 50+ countries for metastatic pancreatic adenocarcinoma. The pipeline includes PEP07 (CHK1 inhibitor, licensed from Sentinel Oncology) and PEP08 (first in-house developed PRMT5:MTA inhibitor, co-developed with XtalPi's AI platform), both in Phase I trials. PharmaEngine also distributes LIPORAXEL® (oral paclitaxel) in Taiwan.
Is PharmaEngine Inc a public or private company?
PharmaEngine Inc is a public company. It is classified as public and is currently operating.
When was PharmaEngine Inc founded?
PharmaEngine Inc was founded in 2003. It employs 11 to 50 people.
Where is PharmaEngine Inc based?
PharmaEngine Inc is headquartered in Paris, France, in the Europe region.
How does PharmaEngine Inc make money?
Three revenue lines are on record. ONIVYDE Royalties and Milestone Payments are the primary driver. The others are ONIVYDE Product Sales (Taiwan) and LIPORAXEL Distribution (Taiwan).
Who are PharmaEngine Inc's main competitors?
Broad incumbents on record are Ipsen, Servier and PharmaMar. Direct peers are Nuvectis Pharma, Cardiff Oncology, IDEAYA Biosciences, Foghorn Therapeutics and Repare Therapeutics. TTY Biopharm is listed as a regional player. XtalPi Holdings is listed as an others.
Does PharmaEngine Inc have an API?
No public API is recorded for PharmaEngine Inc.
What industry is PharmaEngine Inc in?
PharmaEngine Inc's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.